Company news
Botanix Pharmaceuticals Limited (ASX:BOT) news
Botanix Pharmaceuticals Limited news releases on 6ix. Latest, Sep 20, 2023: Response to ASX Price and Volume Query
Press releases — page 2
Response to ASX Price and Volume Query
September 20, 2023
Appendix 4E Preliminary Final Report
August 31, 2023
Appointment of Dr Howie McKibbon as CEO
August 24, 2023
June 2023 Quarterly Activities Report and Appendix 4C
July 30, 2023
Botanix Closes Capital Raising and Royalty Milestone Buyout
July 26, 2023
Botanix Capital Raising to Extinguish Milestone & Royalty
July 21, 2023
Botanix Pharmaceuticals : The West Australian | Botanix Pharmaceuticals secures $12.5m via an institutional placement
July 20, 2023
New Territory Licensed for Sofpironium Bromide with Kaken
June 5, 2023
March 2023 Quarterly Activities Report and Appendix 4C
April 28, 2023
Botanix successfully completes A$10m Placement
April 12, 2023
Botanix Raises A$10 million via Institutional Placement
April 5, 2023
FDA Mid-Cycle Review Meeting Successfully Completed
April 2, 2023
Half Yearly Report and Accounts
February 28, 2023
Press Article Correction
February 14, 2023
Appendix 4C - Quarterly
January 30, 2023
Confirmation Sofpironium Bromide NDA Formally Under Review
December 7, 2022
Placement Completion and Results of Share Purchase Plan
November 28, 2022
Share Purchase Plan Opens
November 8, 2022
A$5 million Institutional Placement and Share Purchase Plan
October 30, 2022
Botanix receives A$3.7m R&D Tax Incentive Refund
October 25, 2022
BOT Announces Promotion and Focus on NDA Approval Readiness
October 20, 2022
Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea
October 12, 2022
BOT Submits FDA New Drug Application for Sofpironium Bromide
September 25, 2022
Issue of First $7.0m Tranche of A$7.5m Placement Completed
September 12, 2022
Botanix Completes Successful A$7.5m Placement
September 1, 2022
Preliminary Final Report
August 30, 2022
Quarterly activities report and Appendix 4C
July 29, 2022
Botanix Pharmaceuticals : Change of Director's Interest Notice * 3
July 7, 2022
Botanix Pharmaceuticals : Application for quotation of securities - BOT
July 7, 2022
NDA Filing Accelerated and Trials Fully Enrolled
July 6, 2022
Dermatology Asset Acquired to Accelerate Path to Revenue
May 4, 2022
Botanix Pharmaceuticals : Appendix 4C - Quarterly
April 28, 2022
FDA Qualified Infectious Disease Product Status for BTX 1801
April 27, 2022
Botanix Pharmaceuticals : Notification regarding unquoted securities - BOT
April 14, 2022
Canine Atopic Dermatitis Program Launched
September 28, 2021
Final Report and Annual Report to Shareholders
August 26, 2021
New Canine Pilot Study Supports Further AD Investigation
May 16, 2021
Botanix Update on BTX 1801 Clinical Development
May 3, 2021
BTX 1702 Rosacea Study Approval
March 29, 2021
Botanix receives A$6.87m R&D Tax Incentive Refund
February 11, 2021
Phase 2a Study Shows BTX 1801 Eradicates S. Aureus
February 2, 2021
Antimicrobial Data Published in Peer-Reviewed Journal
January 19, 2021
Update on BTX 1801 Phase 2a Clinical Study
December 13, 2020
FDA Clears Development Path for BTX 1801
November 10, 2020
Response to ASX Price Query
September 29, 2020
New Antimicrobial Data and Conference Presentation
September 7, 2020
Appendix 4E and Annual Report to Shareholders
August 31, 2020
BTX 1801 Phase 2a Antimicrobial Study Underway
August 11, 2020
Response to ASX Aware Query
July 22, 2020
BTX 1503 End of Phase 2 Milestone with FDA
July 16, 2020